go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Rhode Island rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $512,861 · 10th–90th $489,779$1,584,8930%20%40%10th90th$512,861Professionalmedian $512,861 · 10th–90th $489,779$537,0320%50%10th90th$512,861$100.0K$200.0K$500.0K$1.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$954,992.59
Median
$1,584,893.19
Typical High
$1,584,893.19
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$512,861.38
Typical High
$537,031.80
BCBS
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$512,861.38
BCBS
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$489,778.82
Cigna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$933,254.30
United
Setting
Professional
Modifier
Global
Typical Low
$89,125.09
Median
$363,078.05
Typical High
$537,031.80